Biomea Fusion, Inc. announced positive results from preclinical experiments showing that its investigational drug icovamenib enhances beta cell function and improves the responsiveness of human islets ...

Biomea Fusion, Inc. has presented promising clinical results for icovamenib, a novel therapy aimed at restoring beta-cell function in patients with type 2 diabetes, at the ATTD 2025 Conference.

A new study finds that short, functional-movement and resistance training workouts, called functional high-intensity training (F-HIT), may improve beta-cell function in adults with type 2 diabetes.

Type 2 diabetes (T2D) is a chronic and widely prevalent condition characterized by a progressive loss of glycemic control driven by both insulin resistance and β-cell dysfunction. The disease has long ...

The old antihypertensive drug verapamil may help reduce insulin requirements and hypoglycemic episodes in adults with type 1 diabetes, new research suggests. Results from the study were published ...

Can we predict—and prevent—why transplanted beta cells fail? A preclinical study titled “ChemPerturb-seq screen identifies a small molecule cocktail enhancing human beta cell survival after ...

Unlike our organs, cell organelles such as mitochondria are not fixed in place, but when, where, how, and why organelles move remain unclear. Research published in the Biophysical Journal shows that ...

Scientists at City of Hope have uncovered a gene called SMOC1 that plays a surprising role in the development of type 2 diabetes (T2D) by converting pancreatic cells that normally produce insulin into ...

In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) restored insulin production and ended severe hypoglycemia in adults with type 1 ...

While amyloid β plaques are hallmarks of Alzheimer’s disease (AD), recent research suggests that they aren’t the only players in the neurodegenerative disorder. Genome-wide association studies and RNA ...